The invention relates to a compound of the general formula (iii), its salt, solvate or prodrug, and medical uses surrounding them, where (iii) a1 is selected from n and c-r8； a2 is selected from the group of n and c-r3； a3 is selected from the group of n and c-r9； a4 and a5 and a6 are independently selected from the group of n and c-r1； R 1 is selected from the group of hydrogen, (C 1 -C 3) alkyl, halogen, (C 1 -C 3) alkoxy and (C 1 -C 3) haloalkyl； R2 is selected from hydrogen, halogen and (C1-C3) alkyl； R3 is selected from the group consisting of hydrogen, C1-3 alkylalkyl, nr4r5, (C1-3) alkyl-nr4r5e cyano； wherein r4 and r5 are independently selected from the hydrogen group, (c3-c5) cycloalkyl, (c3-c5) heterocycloalkyl and (c1-c3) alkyl, or r4 and r5 together with the nitrogen atom to which they are attached , form a 5- to 7-membered heterocyclic ring optionally comprising, in addition to the above-mentioned nitrogen atom, another heteroatom group selected from the group consisting of o and nr6, where r6 is selected from the group consisting of hydrogen, methyl, acetyl and formyl； y is selected from the group consisting of o and s； R 7 is selected from the group consisting of hydrogen and (C 1 -C 3) alkyl； R 8 is selected from the group consisting of (C 1 -C 4) alkyl, (C 3 -C 5) cycloalkyl and (C 3 -C 5) heterocycloalkyl； R 9 is selected from the group consisting of hydrogen, (C 1 -C 3) alkyl, (C 1 -C 3) alkoxy； and methods for producing such compounds.a invenção refere-se a um composto da fórmula geral (iii), seu sal, solvato ou pró-fármaco, e utilizações médicas que os envolvem, onde (iii) a1 é selecionado de n e c-r8； a2 é selecionado do grupo de n e c-r3； a3 é selecionado do grupo de n e c-r9； a4 e a5 e a6 são independentemente selecionados do grupo de n e c-r1； r1 é selecio-nado do grupo de hidrogênio, (c1-c3)alquila, halogênio, (c1-c3)alcóxi e (c1-c3)haloalquila； r2 é selecionado de hidrogênio, halogênio e (c1-c3)alquila； r3 é selecionado do grupo que consis
